Luye Pharma Gets US FDA Approval of ERZOFRI Extended-Release Injectable Suspension
Luye Pharma Group has announced that the US Food and Drug Administration (FDA) has approved the company's ERZOFRI (paliperidone palmitate) extended-release injectable suspension, for treating schizophrenia in adults and for treating schizoaffective disorder in adults as monotherapy and as an adjunct to mood stabilizers or antidepressants.
Antidepressants | 30/07/2024 | By Aishwarya | 137
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy